Reference · Frequently Asked Questions
PT-141 Frequently Asked Questions
This reference FAQ addresses commonly searched questions regarding PT-141 (bremelanotide) — its mechanism of action, regulatory status, timing, reported side effects, and how it differs from other pharmacological agents. Answers are derived from published peer-reviewed literature, clinical trial reports, and the FDA-approved prescribing information for Vyleesi® (bremelanotide injection).
All descriptions use evidence-aware language appropriate to the available literature. Where evidence is limited to preclinical or Phase II data, this is stated explicitly. This page does not provide medical advice, dosing guidance, or treatment recommendations. Questions of a clinical nature should be directed to a qualified healthcare provider.
Explore Reference Sections
References
[1] FDA label: Vyleesi® (bremelanotide injection). NDA 210557. Approved June 2019. FDA Label ↗
[2] Kingsberg SA, et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder. Obstet Gynecol. PMID: 31135771
[3] Diamond LE, et al. (2004). Safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141. Int J Impot Res. PMID: 15319053
[4] Giuliano F, et al. (2010). Melanocortin receptor agonists, penile erection, and sexual motivation. Arch Sex Behav. PMID: 20039113
[5] Pfaus JG, et al. (2004). The role of melanocortins in sexual function. Eur J Pharmacol. PMID: 14738942
[6] Rosen RC, et al. (2004). Efficacy and tolerability of PT-141, a melanocortin agonist, in erectile dysfunction. J Sex Med. PMID: 16422951
Educational and informational reference only. Not medical advice. Consult a qualified healthcare provider for clinical guidance.